gototopgototop
PAION AG
Key Visual paion.de

Newsroom 2006

  • Ad hoc release: PAION announces last patient randomised in Phase III ischaemic stroke study (DIAS-2) with Desmoteplase
  • Ad hoc release: PAION AG announces financial results for the first nine months of 2006
  • Ad hoc release: Data Monitoring Committee lifts hold on Phase III study DIAS-2
  • Ad hoc: Recruitment for Phase III stroke study DIAS-2 on hold
  • Ad hoc release: PAION's Desmoteplase may also be useful in haemorrhagic stroke
  • Ad hoc: PAION AG announces financial results for the first half-year and the second quarter of 2006
  • Ad hoc release: PAION and Lundbeck agree on conducting a second Phase III study with Desmoteplase
  • Ad hoc release: PAION's Phase III study on target
  • Ad hoc release: PAION shifts start of Phase I study with Solulin to Q4/2006
  • Ad hoc: PAION AG announces financial results for the first quarter of 2006
  • Ad hoc release: PAION AG reports successful closing of EUR 9.4 million capital increase
  • Ad hoc release: EUR 7 million subordinated loan for growth strategy financing of PAION AG
  • Ad hoc release: PAION AG to issue 1 million shares at EUR 9.44 per share in capital increase
  • Ad hoc release: PAION initiates programme of next generation plasminogen activators
  • Ad hoc release: PAION publishes its consolidated financial results for 2005
  • Ad hoc release: PAION to start Phase IIa study with neuroprotectant Enecadin in acute ischaemic stroke